Literature DB >> 29536496

Relevant tumor sink effect in prostate cancer patients receiving 177Lu-PSMA-617 radioligand therapy.

Christian Filss, Alexander Heinzel, Berthold Miiller, Andreas T J Vogg, Karl-Josef Langen, Felix M Mottaghy.   

Abstract

AIM: In metastatic prostate cancer patients PSMA targeting radioligands have gained significant impact as theranostic probes. In this study a correlation between total tumor volume (TTV) and measured kidney dose as well as salivary glands (SG) uptake in 177Lu-PSMA-617 therapy was evaluated.
METHODS: Eleven consecutive prostate cancer patients receiving a first cylcle of 177Lu-PSMA-617 (administered activity of approximately 6GBq) were included. The 68Ga-PSMA-11 PET/CT scan previous to therapy was used to determine TTV and SG uptake (glandulae submandibularis) employing PMOD version 3.403 with different 68Ga-PSMA-11 thresholds based on the standardized uptake value (SUV).The kidney dose was estimated with the software ULMDOS using planar whole-body scintigrams.
RESULTS: Kidney dose and SG uptake was inversely correlated to TTV, indicating high kidney dose and high SG uptake in case of low tumor load and low kidney dose and low SG uptake in case of high tumor load.
CONCLUSION: Our data support the hypothesis that in 177Lu-PSMA-617 therapy an individualized treatment activity based on total tumor volume could be beneficiary. Schattauer GmbH.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29536496     DOI: 10.3413/Nukmed-0937-17-10

Source DB:  PubMed          Journal:  Nuklearmedizin        ISSN: 0029-5566            Impact factor:   1.379


  14 in total

1.  68Ga-PSMA PET/CT for monitoring response to 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer.

Authors:  Alexander Heinzel; Dima Boghos; Felix M Mottaghy; Florian Gaertner; Markus Essler; Dirk von Mallek; Hojjat Ahmadzadehfar
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-01-29       Impact factor: 9.236

2.  Initial clinical experience performing sialendoscopy for salivary gland protection in patients undergoing 225Ac-PSMA-617 RLT.

Authors:  Hendrik Rathke; Clemens Kratochwil; Ralph Hohenberger; Frederik Lars Giesel; Frank Bruchertseifer; Paul Flechsig; Alfred Morgenstern; Matti Hein; Peter Plinkert; Uwe Haberkorn; Olcay Cem Bulut
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-08-27       Impact factor: 9.236

3.  Peripheral ganglia in healthy rats as target structures for the evaluation of PSMA imaging agents.

Authors:  Heike Endepols; Agnieszka Morgenroth; Boris D Zlatopolskiy; Philipp Krapf; Johannes Zischler; Raphael Richarz; Sergio Muñoz Vásquez; Bernd Neumaier; Felix M Mottaghy
Journal:  BMC Cancer       Date:  2019-06-26       Impact factor: 4.430

4.  Targeting of prostate-specific membrane antigen for radio-ligand therapy of triple-negative breast cancer.

Authors:  Agnieszka Morgenroth; Ebru Tinkir; Andreas T J Vogg; Ramya Ambur Sankaranarayanan; Fatima Baazaoui; Felix M Mottaghy
Journal:  Breast Cancer Res       Date:  2019-10-22       Impact factor: 6.466

5.  Radiation dosimetry of 18F-AzaFol: A first in-human use of a folate receptor PET tracer.

Authors:  Silvano Gnesin; Joachim Müller; Irene A Burger; Alexander Meisel; Marco Siano; Martin Früh; Matthias Choschzick; Cristina Müller; Roger Schibli; Simon M Ametamey; Philipp A Kaufmann; Valerie Treyer; John O Prior; Niklaus Schaefer
Journal:  EJNMMI Res       Date:  2020-04-08       Impact factor: 3.138

6.  Dosing 225Ac-DOTATOC in patients with somatostatin-receptor-positive solid tumors: 5-year follow-up of hematological and renal toxicity.

Authors:  Clemens Kratochwil; Leonidas Apostolidis; Hendrik Rathke; Christos Apostolidis; Felix Bicu; Frank Bruchertseifer; Peter L Choyke; Uwe Haberkorn; Frederik L Giesel; Alfred Morgenstern
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-08-26       Impact factor: 9.236

7.  AAV-Vectored Expression of the Vascular Normalizing Agents 3TSR and Fc3TSR, and the Anti-Angiogenic Bevacizumab Extends Survival in a Murine Model of End-Stage Epithelial Ovarian Carcinoma.

Authors:  Ashley A Stegelmeier; Lisa A Santry; Matthew M Guilleman; Kathy Matuszewska; Jessica A Minott; Jacob G E Yates; Brenna A Y Stevens; Sylvia P Thomas; Sierra Vanderkamp; Kiersten Hanada; Yanlong Pei; Amira D Rghei; Jacob P van Vloten; Madison Pereira; Brad Thompson; Pierre P Major; James J Petrik; Byram W Bridle; Sarah K Wootton
Journal:  Biomedicines       Date:  2022-02-02

8.  Competition ('Steal' Phenomenon) between [68Ga]Ga-PSMA-11 Uptake in Prostate Tumor Tissue Versus Healthy Tissue.

Authors:  Esmée C A van der Sar; Bart de Keizer; Marnix G E H Lam; Arthur J A T Braat
Journal:  Pharmaceutics       Date:  2021-05-11       Impact factor: 6.321

9.  Evaluation of the PSMA-Binding Ligand 212Pb-NG001 in Multicellular Tumour Spheroid and Mouse Models of Prostate Cancer.

Authors:  Vilde Yuli Stenberg; Roy Hartvig Larsen; Li-Wei Ma; Qian Peng; Petras Juzenas; Øyvind Sverre Bruland; Asta Juzeniene
Journal:  Int J Mol Sci       Date:  2021-05-01       Impact factor: 5.923

10.  "Tumour sink effect" on the diagnostic or posttreatment radioiodine scan due to sequestration into large-volume functioning metastasis of differentiated thyroid carcinoma influencing uptake in smaller metastatic sites or remnant thyroid tissue: An uncommon but possible phenomenon in thyroid cancer practice.

Authors:  Sandip Basu; Rohit Ranade; Amit Abhyankar
Journal:  World J Nucl Med       Date:  2020-01-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.